drugset / Trial / NCT05564858
A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label and two-part study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA022-BB05 in participants with advanced/metastatic solid malignant tumors.
Timeline
- Start
- 2023-01-16
- Primary completion
- 2025-09
- Completion
- 2025-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FDA022-BB05 | Monoclonal antibody | — | Intravenous |